Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength

Endocrinology (United States)

Volumn 156, Issue 4, 2015, Pages 1362-1371

  Lim, S V ^a   Marenzana, M ^b   Hopkinson, M ^a   List, E O ^c   Kopchick, J J ^c   Pereira, M ^a   Javaheri, B ^a   Roux, J P ^d   Chavassieux, P ^d   Korbonits, M ^e   Chenu, C ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c OHIO UNIVERSITY   (United States)

^d UNIVERSITÉ DE LYON   (France)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ANIMAL EXPERIMENT; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE LENGTH; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; GROWTH HORMONE BLOOD LEVEL; LUMBAR VERTEBRA; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIBIA; TRABECULAR BONE; TRANSGENIC MOUSE; WEIGHT GAIN; ANIMAL; BODY WEIGHT; BONE; GENETICS; MECHANICAL STRESS; METABOLISM;

ANIMALS; BODY WEIGHT; BONE AND BONES; BONE DENSITY; GROWTH HORMONE; MALE; MICE; MICE, TRANSGENIC; STRESS, MECHANICAL;

EID: 84926431717     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1572     Document Type: Article

References (62)

1. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19:55-79.
2. Ohlsson C, Nilsson A, Isaksson OG, Lindahl A. Effect of growth hormone and insulin-like growth factor-I on DNA synthesis and matrix production in rat epiphyseal chondrocytes in monolayer culture. J Endocrinol. 1992;133:291-300.
3. Tritos NA, Biller BM. Growth hormone and bone. Curr Opin Endocrinol Diabetes Obes. 2009;16:415-422.
4. Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res. 2010;20:1-7.
5. Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci USA. 2002;99:9858-9863.
6. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors and the skeleton. Endocr Rev. 2008;29:535-559.
7. Courtland H-W, Sun H, Beth-On M, et al. Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 Production. J Bone Miner Res. 2011;26:761-768.
8. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202.
9. Thomas JD, Monson JP. Adult GH deficiency throughout lifetime. Eur J Endocrinol. 2009;161:S97-S106.
10. Colao A, Di Somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab. 1999;84:1919-1924.
11. Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab. 2013;98:4808-4815.
12. Padova G, Borzi G, Incorvaia L, et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patient. Clin Cases Miner Bone Metab. 2011;8:37-43.
13. Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures inmenwith active acromegaly. J Clin Endocr Metab. 2008;93:4649-4655.
14. Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol. 2011;164:475-483.
15. Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab. 2013;98:3402-3410.
16. Mormando M, Nasto LA, Bianchi A, et al. Growth hormone receptor isoforms and skeletal fragility in acromegaly. Eur J Endocrinol. 2014;171:237-245.
17. Jean Ho P, Lorraine M, Barkan A, Shaporo B. Bone mineral density of the axial skeleton in acromegaly. J Nucl Med. 1992;33:1608-1612.
18. Kayath Mj, Viera JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporosis Int. 1997;7:226-230.
19. Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity and gonadal function. J Bone Miner Metab. 2006;24:72-78.
20. Madeira M, Neto LV, de Paula Paranhos Neto F, et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013;98:1734-1741.
21. Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly: a potential beneficial effect of growth hormone. Osteoporosis Int. 2004;15:155-159.
22. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 2005;27:1-11.
23. Borah B, Gross GJ, Dufresne TE, et al. Three dimensional microimaging (MRmicroI and microCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec. 2001;265:101-110.
24. Chavassieux P, Seeman E, Delmas PD. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev. 2007;28:151-164.
25. Kopchick JJ, Bellush LL, Coschigano KT. Transgenic models of growth hormone action. Annu Rev Nutr. 1999;19:437-461.
26. Turner ND, Knapp JR, Byers FM, Kopchick JJ. Physical and mechanical characteristics of tibias from transgenic mice expressing mutant bovine growth hormone genes. Exp Biol Med. 2001;226:133-139.
27. Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, Kopchick JJ. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res. 2004;14:309-318.
28. Wolf E, Rapp K, Brem G. Expression of metallothionein-human growth hormone fusion genes in transgenic mice results in disproportionate skeletal gigantism. Growth Dev Aging. 1991;55:117-127.
29. Eckstein F, Lochmüller EM, Koller B, et al. Body composition, bone mass and microarchitectural analysis in GH-transgenic mice reveals that skeletal changes are specific to bone compartment and gender. Growth Horm IGF Res. 2002;12:116-125.
30. Eckstein F, Weusten A, Schmidt C, et al. Longitudinal in vivo effects of growth hormone overexpression on bone in transgenic mice. J Bone Miner Res. 2004;19:802-810.
31. Shah M, Kola B, Bataveljic A, et al. AMP-activated protein kinase (AMPK)activation regulates in vitro bone formation and bone mass. Bone. 2010;147:309-319.
32. Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum. 2011;63:2385-2395.
33. Chappard D, Palle S, Alexandre C, Vico L, Riffat G. Bone embedding in pure methyl methacrylate at low temperature preserves enzyme activities. Acta Histochem. 1987;81:183-190.
34. nd ed. San Diego: Academic Press; 2001:501-509.
35. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols and units for bone histomorphometry. A 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. 2013;28:1-16.
36. Cecim M, Kerr J, Bartke A. Effects of bovine growth hormone (bGH) transgene expression or bGH treatment on reproductive functions in female mice. Biol Reprod. 1995;52:1144-1148.
37. Wanke R, Wolf E, Hermanns W, Folger S, Buchmüller T, Brem G. The GH-transgenic mouse as an experimental model for growth research: clinical and pathological studies. Horm Res. 1992;37:74-87.
38. Wolf E, Rapp K, Wanke R, et al. Growth characteristics of metallothionein-human growth hormone transgenic mice as compared to mice selected for high eight-week body weight and unselected controls. II. Skeleton Growth Dev Aging. 1991;55:237-248.
39. Rosen HN, Chen V, Citadini A, et al. Treatment with growth hormone and IGF-1 in growing rats increases bone mineral content but not bone mineral density. J Bone Miner Res. 1995;10:1352-1358.
40. Palmer AJ, Chung M-Y, List EO, et al. Age-related changes in body composition of bovine growth hormone transgenic mice. Endocrinology. 2009;150:1353-1360.
41. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736-746.
42. Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Abe H, Chihara K. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf). 2001;55:175-181.
43. Biermasz N, Hamdy NAT, Pereira AM, Romijn JA, Roelsema F. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. Eur J Endocrinol. 2005;152:53-60.
44. Chiodini I, Trischitta V, Carnevale V, Liuzzi A, Scillitani A. Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis? J Endocrinol Invest. 2001;24:288-291.
45. Murray RD, Adams JE, Shalet SM. A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J Clin Endocrinol Metab. 2006;91:432-438.
46. Bravenboer N, Holzmann PJ, Ter Maaten PJ, Stururman LM, Roos JC, Lips P. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res. 2005;20:1778-1784.
47. Rejnders CM, Bravenboer N, Holzmann PJ, Bhoelan F, Blankenstein MA, Lips P. In vivo mechanical loading modulates insulin-like growth factor binding protein-2 gene expression in rat osteocytes. Calcif Tissue Int. 2007;80:137-143.
48. Ueland T, Ebbesen EN, Thomsen JS, et al. Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGHBP-5 content in acromegaly. Eur J Clin Invest. 2002;32:122-128.
49. Tseng KF, Bonadio JF, Stewart TA, Baker AR, Goldstein SA. Local expression of human growth hormone in bone results in impaired mechanical integrity in the skeletal tissue of transgenic mice. J Orthop Res. 1996;14:598-604.
50. Steinke B, Patwardhan AG, Havey RM, King D. Human growth hormone transgene expression increases the biomechanical structural properties of mouse vertebrae. Spine. 1999;24:1-4.
51. Kristensen E, Hallfrimsson B, Morck DW, Boyd SK. Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int J Endocrinol. 2012;2012:294965.
52. Roux JP, Wegrzyn J, Arlot ME, et al. Contribution of trabecular and cortical compartments to biomechanical behaviour of human vertebrae: an ex vivo study. J Bone Miner Res. 2010;25:356-361.
53. Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass and metabolic indices. J Clin Endocrinol Metab. 2001;86:4657-4665.
54. Bredella MA, Gerweck AV, Barber LA, et al. Effects of growth hormone administration for 6 months on bone turnover and bone marrow fat in obese premenopausal women. Bone. 2014;62:29-35.
55. Kamenicky P, Blanchard A, Gauci C, et al. Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciura? J Clin Endocrinol Metab. 2012;97:2124-2133.
56. Kopchick JJ, List EO, Kelder B, Gosney ES, Berryman DE. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications. Mol Cell Endocrinol. 2014;386:34-45.
57. Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteoporosis. Int J Endocrinol. 2014;2014:235060.
58. Brooks AJ, Wei Wooh J, Tunny KA, Waters MJ. Growth hormone receptor; mechanism of action. Int J Biochem Cell Biol. 2008;40: 1984-1989.
59. Marie PJ. Signaling pathways affecting skeletal health. Cur. Osteoporosis Rep. 2012;10(3):190-198.
60. Guntur AR, Rosen CJ. IGF-1 regulation of key signalling pathways in bone. Bonekey Rep. 2013;2:437.
61. Ahmed SF, Farquharson C. The effect of GH and IGF1 in linear grow and skeletal development and their modulation by SOCS proteins. J Endocrinol. 2010;206:249-259.
62. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD and diabetic complications. J Bone Miner Res. 2009;24:702-709.